News & Events


  • Compaction simulation as a QbD tool to develop complex oral solid dosage forms

    Last week, Skyepharma contributed to the Compaction Simulation Forum. Through our scientific Poster we presented case studies illustrating the key aspects of Quality by Design approach :  
    Read More
  • Skyepharma invests in state-of-the-art equipment in laboratories capabilities

    April 12, 2018 – Skyepharma’s Analytical Development department recently acquired a BET Analyzer, used for Surface area and Pore Size Analysis. With this new tool, Skyepharma’s dedicated Analytical team is able to study the porous structure of raw materials which impacts the final product properties, such as the dissolution profile, shelf life and bioavailability. This new equipment...
    Read More
  • SKYEPHARMA improves time to market

    February 28, 2018 –   David LESCUYER – EVP Oral Business, Vectura Group of Companies – President of SKYEPHARMA PRODUCTION SAS: “With over 20 years of experience in complex oral solid dosage forms, we help our customers on reformulation, Life Cycle Management, trouble shooting, scale up and technical transfer of their products. Our state of the...
    Read More


  • Skyepharma at Compaction Simulation Forum in San Francisco

    June 12, 2018 – Skyepharma is contributing to San Francisco Compaction Simulation Forum from June 11 to June 13, with a scientific poster about compaction simulation as a QbD tool to develop complex oral solid dosage forms. Indeed, compaction simulation is a powerful tool to accelerate time to market at every stage of drug development,...
    Read More
  • Skyepharma at Vitafoods Europe

    April 23, 2018 – Skyepharma is a key player in the field of development, commercial manufacturing and packaging of complex oral solid dosage forms. We have a reputation for being a reliable partner with tailored capabilities for pharmaceutical, nutraceuticals & food supplement development and manufacturing. We help our clients from the early development stage to...
    Read More
  • Skyepharma will attend CPhI North America in Philadelphia

    April 17, 2018 – As a CDMO, Skyepharma Production SAS is focused on Development and Commercial Manufacturing of Oral Solid Forms. Our site is: FDA Approved, ready for Serialization & Aggregation. We offer Competitive services in : Process Development using Quality by Design Methodology Analytical Methods Development Regulatory Services Contact our Commercial Director to discuss...
    Read More
  • Lucile Kowalski in the ICSE theatre at CPHI WW 2017

    Conference at CPHI Worldwide 2017 with Lucile Kowalski, Project Manager of Skyepharma.
    Read More
  • Skyepharma at CPHI Worldwide 2017

    Interview at CPHI Worldwide 2017 with David Lescuyer, Executive Vice President – Oral Business Unit.
    Read More